Race for approval: biotechs accelerate bipolar disorder therapies 

Summary

Multiple biotechs are accelerating development of new therapies for bipolar disorder, aiming to address unmet medical needs in efficacy and minimize side effects. The article provides general commentary on industry trends without specific clinical data, approvals, or company announcements.